U.S. RESEARCH ROUNDUP- Constellation Energy, Eli Lilly, Talen Energy

Reuters09-13

Sept 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Constellation Energy, Eli Lilly and Talen Energy, on Friday.

HIGHLIGHTS

* Constellation Energy Corp : Jefferies initiates with hold rating; target $183

* Eli Lilly : JP Morgan raises target price to $1,100 from $1,050

* GE Vernova Inc : Evercore ISI raises target price to $240 from $202

* RH : Jefferies raises target price to $294 from $272

* Talen Energy Corp : Jefferies initiates coverage with buy rating; PT $232

Following is a summary of research actions on U.S. companies reported by Reuters on Friday. Stock entries are in alphabetical order.

* Alaska Air Group Inc : TD Cowen raises target price to $52 from $51

* Avantor Inc : RBC raises target price to $34 from $31

* Campbell Soup Co : RBC raises target price to $51 from $47

* Constellation Energy Corp : Jefferies initiates with hold rating; target $183

* Dave & Buster's Entertainment : Piper Sandler cuts target price to $43 from $57

* Dow Inc : RBC cuts target price to $55 from $57

* Edwards Lifesciences Corp : Truist Securities cuts target price to $71 from $82

* Eli Lilly : JP Morgan raises target price to $1,100 from $1,050

* Ferguson Enterprises Inc : Jefferies cuts target price to $235 from $250

* Fulcrum Therapeutics Inc : Leerink Partners cuts target price to $4 from $16

* Fulcrum Therapeutics Inc : Leerink Partners cuts to market perform from

outperform

* Fulcrum Therapeutics Inc : RBC cuts target price to $4 from $15

* Fulcrum Therapeutics Inc : RBC cuts to sector perform from outperform

* GE Vernova Inc : Evercore ISI raises target price to $240 from $202

* GE Vernova Inc : JP Morgan raises target price to $240 from $216

* Halliburton Co : RBC cuts target price to $37 from $44

* Halliburton Co : RBC cuts to sector perform from outperform

* Ibex Ltd : RBC raises target price to $20 from $18

* Johnson & Johnson : HSBC raises target price to $180 from $174

* Kroger Co : Jefferies raises target price to $54 from $53

* Kroger Co : JP Morgan raises target price to $59 from $58

* Labcorp : HSBC raises target price to $240 from $210

* Moderna : Jefferies cuts target price to $65 from $120

* Moderna : Jefferies cuts to hold from buy

* Moderna : Piper Sandler cuts target price to $115 from $157

* Moderna : RBC cuts target price to $75 from $90

* Modivcare Inc : Jefferies cuts target price to $14 from $25

* NRG Energy Inc : Jefferies initiates coverage with hold rating; price target $78

* Oracle Corp : Barclays raises target price to $202 from $172

* Orthopediatrics Corp : Truist Securities raises target price to $34 from $30

* Oruka Therapeutics Inc : Jefferies initiates coverage with buy rating; PT $40

* Public Service Enterprise Group : Jefferies initiates with hold rating; PT $85

* RH : Jefferies raises target price to $294 from $272

* Shoals Technologies Group Inc : Jefferies raises target price to $6 from $5

* Talen Energy Corp : Jefferies initiates coverage with buy rating; PT $232

* Trade Desk Inc : Wedbush raises target price to $115 from $110

* Unity Software Inc : Jefferies raises target price to $20 from $16

* US Bancorp : KBW raises target price to $49 from $46

* Viridian Therapeutics Inc : RBC raises target price to $44 from $35

* Vistra Corp : Jefferies initiates coverage with buy rating; price target $99

* Western Digital Corp : TD Cowen cuts target price to $80 from $95

* Zimmer Biomet Holdings Inc : Truist Securities cuts target to $112 from $117

(Compiled by Bengaluru Newsroom)

((Diaries@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment